Abbott’s Freestyle Libre 2 now approved for adults and children with diabetes

Featuring unsurpassed 14-day accuracy and optional alarms

0
238
Abbott
Now for children (ages 4 and older) and adults with diabetes, this latest technology sustains excellent performance for up to 14 days, providing trends, insights and actionable data on a reader or with the FreeStyle LibreLink mobile app – all at the same price as the current FreeStyle Libre system

Abbott announced its next-generation, sensor-based glucose monitoring technology, FreeStyle Libre 2, received approval by Health Canada for adults and children (4 and older) with diabetes. With new features such as optional, real-time alarms that measure glucose levels every minute, FreeStyle Libre 2 gives users the option to be alerted in real-time critical events such as hypoglycemia (low glucose levels) or hyperglycemia (high glucose levels). Wearable technology, which eliminates the need for painful finger sticks, also provides people with diabetes with excellent accuracy and actionable information to better manage their condition and be priced at the same cost as the current FreeStyle Libre system, it said.

“For the millions of Canadians with diabetes, Abbott’s next-generation FreeStyle Libre 2 system expands on the life-changing capabilities of our original FreeStyle Libre system with enhanced accuracy, optional alarms and now available for children,” said Marie-Flore Nabor, general manager of Abbott’s diabetes care business in Canada. “This latest technology will transform the way diabetes is currently managed. The FreeStyle Libre 2 is designed to simplify this often complicated-to-manage condition and is accessible and affordable to people with diabetes in Canada.”

How FreeStyle Libre 2 works

As the world leader in sensor-based glucose monitoring, Abbott transforms how people with diabetes test their glucose levels. Using Bluetooth technology, the FreeStyle Libre 2 system automatically alerts users when their glucose is high or low without scanning the sensor.

The FreeStyle Libre 2 sensor is worn on the back of the upper arm for up to 14 days and measures glucose every minute to help users and their healthcare providers make informed treatment decisions. With a one-second scan using FreeStyle LibreLink, a smartphone app, or a handheld reader, users can see their glucose reading, trend arrow, and eight-hour history. Users can also share data with their physicians or family members via the LibreLinkUp mobile app.

Abbott′s FreeStyle Libre 2 system utilizes the same proprietary wired enzyme technology as the FreeStyle Libre system, which was the first to remove painful finger sticks associated with better glucose control and decreased time in hypoglycemia and hyperglycemia10, more time in optimal glucose range, and improved HbA1C.

A real-world study published in the British Medical Journal shows that the FreeStyle Libre system’s use over one year is often associated with improved quality of life and that work absenteeism rate and diabetes-related hospital admissions decreased by two thirds.

“Adding an alarm to this glucose sensing technology is definitely a major step to help people with diabetes live more confidently with less fear of high or low glucose levels,” said Bruce Perkins, director, Leadership Sinai Centre for Diabetes and Clinician-Scientist, University of Toronto. “We have seen from research with similar technologies that this kind of innovation can improve glucose level control, and even prevent emergency room visits and hospitalizations. For kids and adults alike, it means less pain from fingersticks, much greater insight into patterns, and much more reassurance.”

Abbott′s FreeStyle Libre 2 system will be available for people with diabetes ages four and up in Canada in the coming months.

As the #1 sensor-based glucose monitoring system used worldwide,6 Abbott’s FreeStyle Libre portfolio has changed the lives of more than 2.5 million people across more than 50 countries. Abbott has also secured partial or full reimbursement for the FreeStyle Libre system in 37 countries, including Canada, where residents of Ontario and Quebec13 who manage diabetes with insulin are covered. Other countries include France, Germany, Japan, the United Kingdom, and the US.

LEAVE A REPLY

Please enter your comment!
Please enter your name here